resources

Alembic Pharmaceuticals Ltd.

NSE: APLLTD

BSE: 533573

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

811.30-18.0 (-2.18%)

8 Jul, 12:00 AM

Overview Analysis Statements Technicals Forecast Peers Resources

News

Annual Reports and Financial Documents

Alembic Pharmaceuticals Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Annual Reports	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	—
Quarterly Results	—	—	—	—	—	Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar
Conference Calls	—	—	—	—	—	—	—	—	13May 2Aug 19Nov	16Feb 9May 10Aug 17Nov	7Feb 12May 9Aug 10Nov	18Jan 9Feb 15May 14Aug 12Nov	12May 11Aug 11Nov	21May
Presentations	—	—	—	—	—	—	—	—	—	—	5May 4Aug 7Nov	5Feb 9May 8Aug 7Nov	3Feb 6May 5Aug 4Nov	5Feb 15May

Corporate Announcements and Regulatory Filings

Alembic Pharmaceuticals Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 20188 Jul 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 30th June, 2026.
Newspaper Publication7 Jul 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed.
Credit Rating1 Jul 2026
Announcement under Regulation 30 (LODR)-Credit Rating
Please find enclosed herewith the Intimation of Re-affirmation of Credit Rating.
Press Release / Media Release26 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapsone Gel, 5%.
Closure of Trading Window26 Jun 2026
Closure of Trading Window
Intimation of Closure of Trading Window.
Newspaper Publication26 Jun 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed.
Press Release / Media Release26 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Oseltamivir Phosphate for Oral Suspension, 6mg/mL.
Analyst / Investor Meet19 Jun 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find enclosed herewith Intimation of One of One Meet.
Analyst / Investor Meet19 Jun 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find enclosed herewith Intimation of One on One Meet.
Analyst / Investor Meet19 Jun 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find enclosed herewith Intimation of One on One Meet.
Press Release / Media Release19 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals Limited received USFDA Tentative Approval for Binimetinib Tablets, 45 mg.
Change in Directorate18 Jun 2026
Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Mr. Sujit Bhayani as Non-Executive Independent Director of the Company w.e.f. 18th June, 2026.
Press Release / Media Release12 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Tretinoin Cream USP, 0.05%.
Credit Rating11 Jun 2026
Announcement under Regulation 30 (LODR)-Credit Rating
Please find enclosed herewith the Intimation regarding re-affirmation of credit rating on Commercial Paper
Newspaper Publication11 Jun 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed.
Press Release / Media Release11 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg.
Newspaper Publication9 Jun 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed.
General6 Jun 2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Company has executed shareholders agreement
General5 Jun 2026
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Please find enclosed herewith specimen copy of the Reminder Letter sent to the shareholders of the Company holding shares in physical form for updating KYC details.
Press Release / Media Release5 Jun 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Haloperidol Tablets, USP.

Frequently Asked Questions

Where can I download the annual report of Alembic Pharmaceuticals Ltd.?

Annual reports of Alembic Pharmaceuticals Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.

Where can I find the quarterly results of Alembic Pharmaceuticals Ltd.?

Quarterly earnings results and presentations of Alembic Pharmaceuticals Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.

Does Alembic Pharmaceuticals Ltd. publish earnings call transcripts?

Earnings call transcripts of Alembic Pharmaceuticals Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.

Where can I find investor presentations of Alembic Pharmaceuticals Ltd.?

Investor presentations and annual day presentations of Alembic Pharmaceuticals Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.

What are the recent corporate announcements of Alembic Pharmaceuticals Ltd.?

Corporate announcements and regulatory filings of Alembic Pharmaceuticals Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.

How do I access the regulatory filings of Alembic Pharmaceuticals Ltd.?

Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Alembic Pharmaceuticals Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.

What is the ISIN of Alembic Pharmaceuticals Ltd.?

The ISIN (International Securities Identification Number) of Alembic Pharmaceuticals Ltd. is INE901L01018. This is the unique identifier used across exchanges and depositories.

On which stock exchange is Alembic Pharmaceuticals Ltd. listed?

Alembic Pharmaceuticals Ltd. is listed on NSE and BSE. The NSE symbol is APLLTD and the BSE code is -.

Where can I find the shareholding pattern of Alembic Pharmaceuticals Ltd.?

The quarterly shareholding pattern of Alembic Pharmaceuticals Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.

How current is the data for Alembic Pharmaceuticals Ltd. on Sharpely?

Share price data for Alembic Pharmaceuticals Ltd. is updated as of 8 Jul 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.